Michael J. E. Neil
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. E. Neil has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
J. Bannister
Department of Anaesthetics, Critical Care and Pain, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
1 shared publicationMegan C. Dale
1 shared publication
Latest Publications
- 1 August 2012
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 117 (2) , 427-428
Predictors of Analgesic Response to Sympathetic Blockade in Complex Regional Syndrome Type 1
To the Editor:
- 1 August 2012
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 117 (2) , 427-428
Predictors of Analgesic Response to Sympathetic Blockade in Complex Regional Syndrome Type 1
To the Editor:
- Open Access
- 1 June 2012
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 13 (6) , 849
Brachial Plexus Block in Phantom Limb Pain: Interesting, but Limited Clinical Benefit in Chronic Setting
- 1 June 2012
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 13 (6) , 849
Open AccessBrachial Plexus Block in Phantom Limb Pain: Interesting, but Limited Clinical Benefit in Chronic Setting
- 1 November 2011
- Published by Bentham Science Publishers Ltd. in Current Clinical Pharmacology
- Vol. 6 (4) , 280-287
Clonidine: Clinical Pharmacology and Therapeutic Use in Pain Management
Pain is an unpleasant sensory perception warning of actual or impending tissue damage. Pain serves a vital physiological role, however, severe and uncontrolled pain in the peri-operative setting can adversely affect outcome from surgery and lead to chronic pain. Multiple neurochemical and receptor processes are involved in pain perception but the role of pro-inflammatory cytokines and adrenergic pathways has only recently been recognised. Clonidine is an agonist at the alpha2-adrenergic receptor that has been in clinical use for over 40 years. Clonidine was recognised at an early stage as having analgesic properties however its systemic use was frequently limited by side-effects. Recent advances in anaesthetic practice, allowing more targeted drug delivery and a better understanding of the basic physiology of pain have led to a re-evaluation of the role of clonidine in pain management. Experimental and clinical studies have identified a diverse action of clonidine in modifying not only the adrenergic component to pain perception but also an important effect on modifying the neurohumoral response to tissue injury. This has implications for the management of a diverse range of pain problems and potentially offers a method of preventing the transition from acute to chronic pain. Clonidine is likely to play an increasing role in clinical practice in anaesthetics and pain management.
- 1 November 2011
- Published by Bentham Science Publishers Ltd. in Current Clinical Pharmacology
- Vol. 6 (4) , 280-287
Clonidine: Clinical Pharmacology and Therapeutic Use in Pain Management
Pain is an unpleasant sensory perception warning of actual or impending tissue damage. Pain serves a vital physiological role, however, severe and uncontrolled pain in the peri-operative setting can adversely affect outcome from surgery and lead to chronic pain. Multiple neurochemical and receptor processes are involved in pain perception but the role of pro-inflammatory cytokines and adrenergic pathways has only recently been recognised. Clonidine is an agonist at the alpha2-adrenergic receptor that has been in clinical use for over 40 years. Clonidine was recognised at an early stage as having analgesic properties however its systemic use was frequently limited by side-effects. Recent advances in anaesthetic practice, allowing more targeted drug delivery and a better understanding of the basic physiology of pain have led to a re-evaluation of the role of clonidine in pain management. Experimental and clinical studies have identified a diverse action of clonidine in modifying not only the adrenergic component to pain perception but also an important effect on modifying the neurohumoral response to tissue injury. This has implications for the management of a diverse range of pain problems and potentially offers a method of preventing the transition from acute to chronic pain. Clonidine is likely to play an increasing role in clinical practice in anaesthetics and pain management.
- 1 June 2009
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 108 (6) , 1867-1868
Hypokalaemia with Severe Rebound Hyperkalaemia After Therapeutic Barbiturate Coma
Severe disturbance of potassium balance is a rare but life-threatening complication of therapeutic barbiturate coma. A 14-yr-old patient was treated with a thiopental infusion for management of increased intracranial pressure after severe head injury. The patient had persistent hypokalaemia during the thiopental infusion. On cessation of the infusion the patient rapidly developed a tachydysrhythmia associated with a serum K+ of 7.0. Possible mechanisms of this phenomenon are discussed. We conclude that aggressive treatment of hypokalaemia during barbiturate coma should be avoided, and advocate a tapering dose of thiopental and not abrupt cessation of an infusion.
- 1 June 2009
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 108 (6) , 1867-1868
Hypokalaemia with Severe Rebound Hyperkalaemia After Therapeutic Barbiturate Coma
Severe disturbance of potassium balance is a rare but life-threatening complication of therapeutic barbiturate coma. A 14-yr-old patient was treated with a thiopental infusion for management of increased intracranial pressure after severe head injury. The patient had persistent hypokalaemia during the thiopental infusion. On cessation of the infusion the patient rapidly developed a tachydysrhythmia associated with a serum K+ of 7.0. Possible mechanisms of this phenomenon are discussed. We conclude that aggressive treatment of hypokalaemia during barbiturate coma should be avoided, and advocate a tapering dose of thiopental and not abrupt cessation of an infusion.